The stock of Legend Biotech Corp ADR (LEGN) has gone down by -4.61% for the week, with a -2.15% drop in the past month and a 23.85% rise in the past quarter. The volatility ratio for the week is 3.48%, and the volatility levels for the past 30 days are 3.17% for LEGN. The simple moving average for the past 20 days is -4.60% for LEGN’s stock, with a -1.11% simple moving average for the past 200 days.
Is It Worth Investing in Legend Biotech Corp ADR (NASDAQ: LEGN) Right Now?
The 36-month beta value for LEGN is at 0.11. Analysts have varying views on the stock, with 15 analysts rating it as a “buy,” 7 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LEGN is 181.45M, and currently, shorts hold a 5.90% of that float. The average trading volume for LEGN on September 06, 2024 was 966.51K shares.
LEGN) stock’s latest price update
Legend Biotech Corp ADR (NASDAQ: LEGN)’s stock price has plunge by -5.82relation to previous closing price of 57.39. Nevertheless, the company has seen a -4.61% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-20 that SOMERSET, N.J., Aug. 20, 2024 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on Wednesday, September 4, 2024, at 2:35 p.m. ET.
Analysts’ Opinion of LEGN
Many brokerage firms have already submitted their reports for LEGN stocks, with Truist repeating the rating for LEGN by listing it as a “Buy.” The predicted price for LEGN in the upcoming period, according to Truist is $88 based on the research report published on June 17, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LEGN reach a price target of $73, previously predicting the price at $86. The rating they have provided for LEGN stocks is “Buy” according to the report published on May 24th, 2024.
Deutsche Bank gave a rating of “Buy” to LEGN, setting the target price at $60 in the report published on May 23rd of the current year.
LEGN Trading at 0.03% from the 50-Day Moving Average
After a stumble in the market that brought LEGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.60% of loss for the given period.
Volatility was left at 3.17%, however, over the last 30 days, the volatility rate increased by 3.48%, as shares sank -1.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.20% upper at present.
During the last 5 trading sessions, LEGN fell by -4.61%, which changed the moving average for the period of 200-days by -14.99% in comparison to the 20-day moving average, which settled at $56.61. In addition, Legend Biotech Corp ADR saw -10.17% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for LEGN
Current profitability levels for the company are sitting at:
- -0.76 for the present operating margin
- 0.57 for the gross margin
The net margin for Legend Biotech Corp ADR stands at -0.63. The total capital return value is set at -0.23. Equity return is now at value -22.21, with -15.29 for asset returns.
Based on Legend Biotech Corp ADR (LEGN), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -0.47. The debt to equity ratio resting at 0.25. The interest coverage ratio of the stock is -15.49.
Currently, EBITDA for the company is -421.76 million with net debt to EBITDA at -0.42. When we switch over and look at the enterprise to sales, we see a ratio of 22.01. The receivables turnover for the company is 4.5for trailing twelve months and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.84.
Conclusion
In conclusion, Legend Biotech Corp ADR (LEGN) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
